

Research Article

Cardiovascular Complications are rare in Severe COVID-19 Presenting with Myocardial Injury

Verda Loxley^{1*}, Daisy Parks², Simon Gildon²

¹*Department of Medicine, Division of Cardiology, University of California San Francisco School of Medicine, San Francisco, CA, USA

²Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA

*Correspondence: Verda Loxley, Department of Medicine, Division of Cardiology, University of California San Francisco School of Medicine, San Francisco, CA, USA. E-mail: verdaloxy@gmail.com, DOI: 10.1042/JIDT.5.1.0021

Abstract

Background: SARS-COV2 infection has been linked to cardiovascular complications. Previously published data suggested that cardiac injury may be a common disease feature and contribute to morbidity and mortality in severe COVID-19. Since the early days of the pandemic, little data has emerged describing what cardiovascular complications arise from myocardial injury in severe COVID-19 and whether these complications contribute to mortality.

Objectives: Describe the incidence and nature of cardiovascular complications in patients with severe COVID-19 infection and biochemical or imaging evidence of myocardial injury.

Methods: We analyzed consecutive patients admitted for severe COVID-19 and presenting with biochemical or echocardiographic evidence of myocardial injury across 16 centers within the CARDIO-COVID investigator-initiated consortium. A light-GBM machine learning model was used to identify variables associated with mortality.

Study outcomes: Our study included 1,328 patients. In hospital mortality was 29.4%. Factors most associated with mortality were age, SOFA Cardiovascular score, elevated troponin, intubation, high vasoactive-inotropic score (VIS), high PEEP, and high FiO₂. Cardiovascular complications were rare and did not present significant association with mortality. Patients with high VIS and SOFA Cardiovascular scores had a significantly higher incidence of secondary bacterial pneumonias suggesting septic shock played a role in their physiology. Investigator-adjudicated cause of death data identified respiratory failure and septic shock as primary causes of mortality.

Conclusion: Cardiovascular complications of severe COVID-19 are uncommon and do not seem to contribute significantly to mortality. Biochemical markers of myocardial injury or strain still carry significant prognostic value, but the value of these markers may indicate presence of high-risk ARDS phenotypes as opposed to significant myocardial injury.

Keywords: COVID-19, Cardiovascular, Myocardial injury, Heart failure cohorts, Lung injury, SARS-CoV-2

Received date: January 08, 2026; **Accepted date:** January 20, 2026; **Published date:** February 09, 2026

Citation: Verda Loxley, Daisy Parks, Simon Gildon (2026) Cardiovascular Complications are rare in Severe COVID-19 Presenting with Myocardial Injury. JN 5:1

Copyright: © 2026, Verda Loxley. All intellectual property rights, including copyrights, trademarks rights and database rights with respect to the information, texts, images, logos, photographs and illustrations on the website and with respect to the layout and design of the website are protected by intellectual property rights and belong to Publisher or entitled third parties. The reproduction or making available in any way or form of the contents of the website without prior written consent from Publisher is not allowed.

Introduction

The specter of impending cardiac failure has loomed over patients admitted with severe Coronavirus Disease 2019 (COVID-19) since the beginning of the pandemic [1]. Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) is known to enter host cells via the Angiotensin Converting Enzyme-2 (ACE2) receptor, which is heavily expressed in human myocardium [2]. Early reports of elevated troponin

and NT-proBNP being predictive of severe COVID-19 raised concerns that myocardial injury played a significant role in severe disease [3-5]. Studies describing high rates of left ventricular dysfunction and various arrhythmias furthered this hypothesis, and contributed to the supposition of SARS-CoV-2 myocarditis as a common feature of COVID-19 [6-8].

Conflicting studies have emerged. Large cardiovascular databases suggest that cardiogenic shock and cardiovascular events are rare complications of COVID-19, yet the narrative supporting increased rates of myocarditis and death at the population level suggest that COVID-19 continues to have a large impact on cardiovascular health [9, 10]. Small cohort studies phenotyped patients suffering from acute cardiac failure due to severe COVID-19 showed Multisystem Inflammatory Syndrome (MIS-A) as a cause of de novo cardiac failure [11], but patients suspected to have myocarditis without fitting this clinical syndrome rarely demonstrate histologic evidence to support the diagnosis [12]. Imaging studies have shown that ventricular dysfunction may contribute some predictive value for death but likely presents more as a sequela of hypoxemia and elevated pulmonary vascular resistance than primary myocardial injury [13, 14].

The objective of this study was to investigate the frequency of cardiovascular complications in patients with severe COVID-19 and develop a predictive model describing how cardiovascular complications contribute to mortality. Contrary to earlier concerns regarding myocardial complications, we hypothesized that mortality among ICU patients with severe COVID-19 and evidence of myocardial involvement is primarily driven by respiratory complications, rather than cardiovascular complications.

Methods

Study Design and Patient Cohort

This is an ambidirectional multicenter cohort study conducted at 16 hospitals through a multi-national, investigator-initiated research network (CARDIO-COVID) of critical care physicians from the United States, Canada, Switzerland, and France. We included patients admitted to the ICU with COVID-19 and evidence of myocardial injury between April 2020 and April 2022. The data instrument was designed to define the cardiovascular effects of COVID-19 in critically ill patients with evidence of myocardial injury and predict how cardiovascular effects contribute to mortality. Myocardial injury was defined as a troponin above the upper limit of normal, BNP or NT-proBNP > 10% the upper limit of normal, newly identified ejection fraction < 50%, or a new drop in ejection fraction by > 10% from baseline. The primary outcome was death during hospital admission. Data were collected both retrospectively and prospectively through comprehensive chart review and entered into a REDCap Database (Appendix 1). The CARDIO-COVID protocol and waiver of consent were approved by the Institutional Review Board at Stanford University and each of the participating centers. Stanford University School of Medicine served as the coordinating center. TRIPOD and STROBE Statement principles were adhered to and checklist completed.

Outcomes

Our primary outcome of interest was hospital mortality (or survival). Secondary outcomes were intubation, cardiac arrest, myocardial infarction, myocarditis, new onset heart failure, and stroke.


Data collection

The data instrument collected patient demographics, comorbidities, cardiovascular complications (stroke, myocardial infarction, new onset heart failure, arrhythmia, cardiac arrest, myocarditis, and pulmonary embolism), infectious complications, and utilization data for advanced ICU therapies including dialysis, intubation, and mechanical circulatory support. Serial data were collected for the first 15 days of ICU admission including: vital signs, labs, supplemental oxygen therapy, non-invasive positive pressure therapies, ventilator settings, and vasoactive medications and doses.

Statistical analysis

We summarized vital signs, labs and ICU resource utilization according to inpatient mortality. Due to a high degree of missingness within the cohort, a “missing data” category was established for all demographic and outcome variables. We employed descriptive statistics and Absolute Standardized Differences (ASDs) to compare patients who died with those who did not. Categorical variables were presented as counts and percentages, while continuous variables were summarized as mean values along with their Standard Deviation (std). ASD measures of 0.2, 0.5, 0.8, and 1.3 corresponded to differences between the groups characterized as very small, small, medium, large, and very large, respectively. Given broad dynamic ranges and low event rates at individual date points, continuous variables were dichotomized and high-risk categories defined based on the value that maximized the Youden’s J Statistic; peak FiO₂ > 60% for intubated, FiO₂ > 50% for non-intubated patients, troponin I > 0.04 ng/mL, troponin T > 0.01 ng/mL, and PEEP > 10 cm H₂O.

FiO₂, troponin and PEEP had a high rate of missing data (**Table 1**). Instead of excluding these variables that could potentially influence mortality, we treated the missing data as a separate category and incorporated these variables into our prediction model. Given the high proportion of intubated patients, we differentiated higher risk lung injuries within that cohort. We determined threshold values for each variable by Receiver Operator Curves (ROC) (**Supplementary Figure 1**).



Supplementary Figure 1: Receiver operator curves showing AUCs and thresholds associated with high-risk for mortality.

	Overall (N=1328)	Died (N=391)	Didn't Die (N=937)	ASD
Age (years)				
Mean (SD)	65 (15.6)	69.6 (13.6)	62.4 (16.1)	0.478
≤ 65	459 (34.6%)	116 (29.7%)	343 (36.6%)	0.448
> 65	538 (40.5%)	244 (62.4%)	294 (31.4%)	0.448
Missing	331 (24.9%)	31 (7.9%)	300 (32%)	0.632

Sex				
Female	473 (35.6%)	154 (39.4%)	319 (34%)	0.144
Male	594 (44.7%)	233 (59.6%)	361 (38.5%)	0.144
Race/Ethnicity				
Hispanic	103 (7.8%)	32 (8.2%)	71 (7.6%)	0.023
Non-Hispanic American Indian/Alaskan Native	2 (0.2%)	0 (0%)	2 (0.2%)	0.065
Non-Hispanic Asian	51 (3.8%)	31 (7.9%)	20 (2.1%)	0.267
Non-Hispanic Native Hawaiian or Pacific Islander	3 (0.2%)	0 (0%)	3 (0.3%)	0.08

Journal of Infectious Diseases and Therapy					Open access
Non-Hispanic Black or African American	454 (34.2%)	151 (38.6%)	303 (32.3%)	0.132	
Non-Hispanic White	339 (25.5%)	119 (30.4%)	220 (23.5%)	0.157	
Unknown / Not Reported	376 (28.3%)	58 (14.8%)	318 (33.9%)	0.456	
Medical History					
Hypertension	767 (57.8%)	279 (71.4%)	488 (52.1%)	0.405	
Diabetes	517 (38.9%)	204 (52.2%)	313 (33.4%)	0.386	
Asthma	60 (4.5%)	25 (6.4%)	35 (3.7%)	0.121	
Chronic obstructive pulmonary disease	119 (9%)	54 (13.8%)	65 (6.9%)	0.227	
Chronic lung disease	43 (3.2%)	22 (5.6%)	21 (2.2%)	0.175	
Chronic kidney disease	269 (20.3%)	96 (24.6%)	173 (18.5%)	0.149	
Chronic dialysis	59 (4.4%)	23 (5.9%)	36 (3.8%)	0.095	
Coronary artery disease	183 (13.8%)	82 (21%)	101 (10.8%)	0.282	
Solid organ transplant	28 (2.1%)	13 (3.3%)	15 (1.6%)	0.111	
Heart failure with preserved ejection fraction	97 (7.3%)	39 (10%)	58 (6.2%)	0.139	
Heart failure with reduced ejection fraction	64 (4.8%)	31 (7.9%)	33 (3.5%)	0.191	
Bone marrow transplant	2 (0.2%)	2 (0.5%)	0 (0%)	0.101	
LVAD implantation	3 (0.2%)	1 (0.3%)	2 (0.2%)	0.009	
Atrial fibrillation	175 (13.2%)	68 (17.4%)	107 (11.4%)	0.171	
Severe cardiac valvular disease	31 (2.3%)	12 (3.1%)	19 (2%)	0.066	
Pulmonary hypertension diagnosis	29 (2.2%)	10 (2.6%)	19 (2%)	0.035	
Malignancy	83 (6.2%)	43 (11%)	40 (4.3%)	0.255	
None of the above	108 (8.1%)	30 (7.7%)	78 (8.3%)	0.024	
Outcomes					
Myocarditis	45 (3.4%)	27 (6.9%)	18 (1.9%)	0.244	
Stroke	44 (3.3%)	19 (4.9%)	25 (2.7%)	0.115	
Intubation	497 (37.4%)	290 (74.2%)	207 (22.1%)	1.221	
STEMI	27 (2%)	17 (4.3%)	10 (1.1%)	0.203	
New Heart Failure	55 (4.1%)	29 (7.4%)	26 (2.8%)	0.212	
Cardiac Arrest	54 (4.1%)	51 (13%)	3 (0.3%)	0.527	
Chest Compressions	47 (3.5%)	39 (10%)	8 (0.9%)	0.394	
Pneumonia	182 (13.7%)	106 (27.1%)	76 (8.1%)	0.515	
Torsades de Pointes / Sustained Ventricular Tachycardia	44 (3.3%)	27 (6.9%)	17 (1.8%)	0.251	
Atrial Fibrillation / Atrial Flutter / Sustained Supraventricular Tachycardia	211 (15.9%)	117 (29.9%)	94 (10%)	0.514	

Bradycardia requiring therapy	37 (2.8%)	22 (5.6%)	15 (1.6%)	0.217
VIS Max				
VIS > 0: Mean (SD)	193.1 (218.5)	248.7 (225.4)	110.6 (178.8)	0.681
VIS = 0	573 (43.1%)	104 (26.6%)	469 (50.1%)	0.987
SOFA Cardiovascular				
0	508 (38.3%)	71 (18.2%)	437 (46.6%)	1.166
1	14 (1.1%)	9 (2.3%)	5 (0.5%)	0.137
2	4 (0.3%)	1 (0.3%)	3 (0.3%)	0.032
3	234 (17.6%)	124 (31.7%)	110 (11.7%)	0.407
4	212 (16%)	146 (37.3%)	66 (7%)	0.753
Missing	356 (26.8%)	40 (10.2%)	316 (33.7%)	0.592
Troponin Max				
Normal	74 (5.6%)	23 (5.9%)	51 (5.4%)	0.32
High Risk	416 (31.3%)	221 (56.5%)	195 (20.8%)	0.32
Missing	838 (63.1%)	147 (37.6%)	691 (73.7%)	0.781
FiO2 Max				
Normal	96 (7.2%)	22 (5.6%)	74 (7.9%)	0.599
High Risk	355 (26.7%)	206 (52.7%)	149 (15.9%)	0.599
Missing	877 (66%)	163 (41.7%)	714 (76.2%)	0.749
PEEP Max (in Intubated or BiPAP patients)				
> 10	174 (13.1%)	109 (27.9%)	65 (6.9%)	0.016
≤10	93 (7%)	59 (15.1%)	34 (3.6%)	0.016

Table 1: Depicts cause risk of death associated with demographic and clinical variables.

To assess the predictive capacity of clinical characteristics for mortality, we employed 23 clinical features including age, Vasoactive-Inotropic Score (VIS), Sequential Organ Failure Assessment (SOFA) cardiovascular score, Troponin, Peep, and FiO2. A Light Gradient Boosting Machine (LightGBM) model was developed using these features. The dataset was partitioned into training (60%), validation (20%), and testing (20%) subsets. Hyperparameter tuning was performed on the validation dataset using Bayesian optimization. Model performance was subsequently evaluated on the test dataset, considering sensitivity, specificity, and the Area Under the Curve (AUC) with two-sided 95% Confidence Intervals (CIs). Furthermore, we utilized the Shapley Additive Explanation (SHAP) method to assess the individual impact of each feature on the likelihood of mortality. A SHAP value closer to 0 means that no relationship can be established between a variable and outcome of interest while values closer 1 suggest a stronger relationship. Patients with new onset heart failure were analyzed separately to assess whether systemic complications of cardiac failure bore a greater relationship with mortality in this population. SHAP was further utilized to assess in detail the factors and their interactions that are most associated with mortality. All analyses were performed using Python and R programming languages.

Results

A total of 1328 patients were entered into the CARDIO-COVID registry, among whom 391 (29.4%) experienced mortality. The mean (std) age

was 65 (15.6) years, with 594 (44.7%) being male, and 103 (7.8%) identifying as Hispanic. The predominant comorbidities were hypertension (57.8%), diabetes (38.9%) and chronic kidney diseases (20.3%). **(Table 1)**. Within the cohort 497 (37.4%) patients required intubation, 55 (4.1%) experienced new onset heart failure, 54 (4.1%) experienced cardiac arrest, 45 (3.4%) were thought to have myocarditis, 44 (3.3%) experienced a stroke, 27 (2.7%) experienced STEMI. Distribution of patients by center is shown in **Supplementary Table 1**.

Participating Center	Patients Entered
Ochsner Medical Center	641
Emory University	128
Medstar Medical Center	99
University of Toronto	92
Stanford University	80
Feinstein Institute of Medical Research	79
Centre Hospitalier de L'Université de Montréal	51
University of Pennsylvania	35
University of Zurich	26
Université de Sherbrooke	23
University of California Los Angeles	21
University of Albany	14
University of Nebraska	13
Wake Forest University	5
Clinique Ambroise Paré Neuilly	2
Massachusetts General Hospital	1

Supplementary Table 1: Patients entered per center.

Cause of death data further supported respiratory failure and hypoxemia as the leading cause of mortality (**Figure 1**). Cause of death in rank order were hypoxemic respiratory failure (N=106, 65.4%), septic shock (N=17, 10.5%), cardiac arrest due to Pulseless Electrical Activity (PEA) (N=15, 9.3%), cardiac failure (N=5, 3.1%), cerebrovascular accident (N=3, 1.9%), and hemorrhagic shock (N=2, 1.2%). Of patients who died of cardiovascular complications: 1 died of an NSTEMI, 1 died of bradycardia, 1 died of cardiogenic shock, and two experienced cardiogenic shock in the context of multiorgan failure.




Figure1: Depicts cause of death (N=391) as adjudicated by site investigators.

Table 1 presents descriptive statistics of patients who experienced mortality, in comparison with those who survived. As anticipated, the proportion of older patients was higher in the mortality group compared to those who survived (62.4% vs. 31.4%, ASD=0.45). Consistent with previous findings [7, 15], the mortality group demonstrated an elevated prevalence of comorbid conditions such as hypertension (71.4% vs. 52.1%, ASD: 0.41), diabetes (52.2% vs. 33.4%, ASD:0.39) and coronary artery disease (21% vs. 10.8%, ASD:0.28). On the contrary, differences in male patients (63.2%, vs. 53.1%, ASD:0.14) or those with atrial fibrillation (17.4% vs. 11.4%, ASD:0.17) and chronic kidney disease (24.6% vs. 18.5%, ASD:0.15) were small of the outcomes, intubation (74.2% vs. 22.1%, ASD:1.22), concomitant bacterial pneumonia (27.1% vs. 8.1%, ASD:0.52), and new onset a-fib (29.9% vs. 10%, ASD:0.51) were both common in the mortality group. Stroke, myocardial infarction, ventricular dysrhythmias, pulmonary embolism, myocarditis and new onset heart failure were uncommon and presented similar incidences in both survivors and non-survivors of the clinical variables, maximum VIS score, SOFA Cardiovascular Score, PEEP, FiO₂, and serum troponin demonstrated medium to large differences between the mortality and surviving groups. PEEP >10 cm H₂O showed the largest difference between the groups (27.9% vs 6.9%, ASD 0.86). Similarly, high risk category in FiO₂ demonstrated a large difference (52.7% vs 15.9%, ASD 0.60), while combined troponin T and I above cutoff showed a medium difference between the groups (56.5% vs 20.8%, ASD 0.32).

Our LightGBM model was tested on 266 patients, with 78 (29.3%) patients experiencing mortality. The model achieved an accuracy of 80.1%, sensitivity of 78.2%, specificity of 80.9%, and an AUC of 0.89 (95% CI, 0.85-0.93) (**Figure 2**). The most important variable predicting mortality was age, followed by higher SOFA Cardiovascular, need for intubation, and elevated troponin (**Figure 3**). The presence of PEA had a strong relationship with mortality, but the absence was not protective, which is why its association with mortality was less than the aforementioned variables. The likelihood of mortality increased with higher values of the respective variables. Importantly, cardiovascular complications including new onset heart failure, ventricular tachycardia/fibrillation, and suspected myocarditis showed very little predictive value for mortality.




Figure 2: Depicts sensitivity and specificity of the Light GBM model.



Figure 3: Graphical depiction of relative impact each clinical variable had on risk of death in the light GBM model. Data elements at the top carried the greatest association with mortality. The entire CARDIO COVID cohort shown on the left and heart failure cohort on the right. Each hash mark represents an individual patient.

To achieve better insights into how hemodynamic compromise and lung injury relate to one another with respect to risk of death we performed 3D SHAP plots plotting three variables simultaneously, which can be seen in **Figure 4**. When separated by age > 65 or < 65 (**Figure 4a**), older patients who were not intubated had a higher risk of death despite having lower SOFA Cardiovascular score. Within patients older than 65, non-intubated patients who died had a mean age of 79 compared to 76 for intubated patients who died (p=0.003).

When patients were segregated by intubation status, SOFA Cardiovascular, and VIS (**Figure 4b**), a separation appears where the patients at greatest risk for mortality were intubated patients with low SOFA Cardiovascular and VIS scores. This may reflect the presence of a treatable process like secondary bacterial pneumonia and septic shock driving respiratory decompensation in patients with higher SOFA scores while intubated patients with low SOFA scores succumbed to irreversible viral lung injury without sepsis. In the intubated cohort bacterial pneumonia was reported more in patients with a SOFA Cardiovascular score > 1 in 25.8% vs 5.3% in those with SOFA score < 1 (ASD: 0.59).

When patients are segregated by SOFA Cardiovascular score and then analyzed by exposure to intubation and chest compressions we see further separation of populations. **Figure 4c** shows that patients with higher SOFA Cardiovascular scores, greater exposure to intubation, and exposure to chest compressions carried the highest risk for mortality. Patients with a SOFA score greater than 1 had a significantly higher risk of pneumonia suggesting septic shock contributed to higher scores (5.3% vs 24.9%, p=0.0001, **Supplementary Table 2**). Again, the elderly, non-intubated cohort at high risk for mortality is shown as an outlier population in the SOFA Cardiovascular score of 1 category.

General Cohort								
	Overall (N=1328)	SOFA Cardiovascular=0 (N=508)	SOFA Cardiovascular=1 (N=14)	SOFA Cardiovascular=2 (N=4)	SOFA Cardiovascular=3 (N=234)	SOFA Cardiovascular=4 (N=212)	p	ASD
Pneumonia	182 (13.7)	17 (3.3)	1 (7.1)	0 (0.0)	39 (16.7)	112 (52.8)	<0.001	0.7
Heart Failure Cohort								
	Overall (N=55)	SOFA Cardiovascular=0 (N=14)	SOFA Cardiovascular=1 (N=0)	SOFA Cardiovascular=2 (N=1)	SOFA Cardiovascular=3 (N=12)	SOFA Cardiovascular=4 (N=27)	p	ASD
Pneumonia	14 (25.5)	1 (7.1)	0 (0.0)	0 (0.0)	3 (25.0)	10 (37.0)	0.198	0.638

Supplementary Table 2: Patients diagnosed with secondary bacterial or fungal pneumonia analyzed by SOFA Cardiovascular score. Separation of patients demonstrates risk of greater hemodynamic compromise in patients diagnosed with pneumonia reflecting increased risk of septic shock.




Figure 4: Depicts contribution of high-risk variables to individual patient SHAP value. Color and dot size reflect additional high-risk variables describing mechanism of injury associated with variable in question. Dots represent individual patients. a) When patients analyzed by age, even distribution of SOFA Cardiovascular scores and intubation status demonstrates that age carries the greatest risk of death. b) Analyzing by intubated status highlights the population with likely isolated viral pneumonia and low SOFA Cardiovascular and VIS scores. c) When analyzed by SOFA Cardiovascular score, increasing risk and complications of hemodynamic compromise likely driven by septic shock and chest compressions is demonstrated. d) Analysis by troponin level demonstrates increasing SHAP values but even distribution of indicators of hemodynamic compromise suggesting troponin does not implicate cardiac failure.

In **Figure 4d** patients are segregated by high-risk or low-risk troponin status; serum troponin above the upper limit of normal were associated with mortality. Within this cohort, the act of checking a troponin carried predictive value for death. The average troponin and dynamic range were narrow precluding clinically meaningful evaluation of troponin as a continuous variable.

Given low event rates, we were unable to analyze outcomes specifically within populations of patients who experienced cardiovascular complications except for patients with newly identified Heart Failure with Reduced Ejection Fraction (HFrEF). Within this population the mortality rate was 54.3% (38/70). The higher mortality rate in this cohort was most attributable to age. The mean (std) age for HFrEF patients who died was older [67.5(12.9), ASD: 0.71], compared to patients who survived [55.2 (17.2)]. Ejection fraction did not differ significantly between survivors and non-survivors (39.4 (10.2) vs 37.4 (12.7), $p=0.7$) within the heart failure population predictors of death were similar to the overall cohort with the exception of SOFA Cardiovascular and VIS scores (**Table 2**). Absolute VIS scores were higher within the heart failure population compared to the general cohort. Light GBM analysis similarly demonstrates that elevated SOFA Cardiovascular and VIS scores carry greater predictive value for death in the heart failure cohort than the general cohort. Secondary bacterial or fungal pneumonia was more common in heart failure patients with SOFA Cardiovascular scores > 1 suggesting septic shock may be contributing to increased SOFA Cardiovascular and VIS scores.


	Overall (N=55)	Died (N=29)	Didn't Die (N=26)	ASD
Age (years)				
Mean (SD)	60.6 (15.9)	65.7 (12.9)	55.2 (17.2)	0.71
≤65	27 (49.1%)	11 (37.9%)	16 (61.5%)	0.468
> 65	22 (40%)	14 (48.3%)	8 (30.8%)	0.468
Missing	6 (10.9%)	4 (13.8%)	2 (7.7%)	0.198
Sex				
Female	19 (34.5%)	10 (34.5%)	9 (34.6%)	0.003
Male	36 (65.5%)	19 (65.5%)	17 (65.4%)	0.003
Race/Ethnicity				
Hispanic	5 (9.1%)	1 (3.4%)	4 (15.4%)	0.418
Non-Hispanic American Indian/Alaskan Native	1 (1.8%)	0 (0%)	1 (3.8%)	0.283
Non-Hispanic Asian	9 (16.4%)	6 (20.7%)	3 (11.5%)	0.251
Non-Hispanic Native Hawaiian or Pacific Islander	0 (0%)	0 (0%)	0 (0%)	0
Non-Hispanic Black or African American	13 (23.6%)	9 (31%)	4 (15.4%)	0.377
Non-Hispanic White	15 (27.3%)	8 (27.6%)	7 (26.9%)	0.015
Unknown / Not Reported	12 (21.8%)	5 (17.2%)	7 (26.9%)	0.235
Medical History				
Hypertension	35 (63.6%)	22 (75.9%)	13 (50%)	0.556
Diabetes	33 (60%)	19 (65.5%)	14 (53.8%)	0.24
Asthma	5 (9.1%)	3 (10.3%)	2 (7.7%)	0.093
Chronic obstructive pulmonary disease	5 (9.1%)	4 (13.8%)	1 (3.8%)	0.356
Chronic lung disease	2 (3.6%)	2 (6.9%)	0 (0%)	0.385
Chronic kidney disease	16 (29.1%)	9 (31%)	7 (26.9%)	0.091
Chronic dialysis	3 (5.5%)	2 (6.9%)	1 (3.8%)	0.136
Coronary artery disease	11 (20%)	7 (24.1%)	4 (15.4%)	0.221
Solid organ transplant	4 (7.3%)	3 (10.3%)	1 (3.8%)	0.255
Heart failure with preserved ejection fraction	2 (3.6%)	1 (3.4%)	1 (3.8%)	0.021
Heart failure with reduced ejection fraction	13 (23.6%)	7 (24.1%)	6 (23.1%)	0.025
Bone marrow transplant	0 (0%)	0 (0%)	0 (0%)	0
LVAD implantation	0 (0%)	0 (0%)	0 (0%)	0
Atrial fibrillation	4 (7.3%)	1 (3.4%)	3 (11.5%)	0.311
Severe cardiac valvular disease	2 (3.6%)	1 (3.4%)	1 (3.8%)	0.021
Pulmonary hypertension diagnosis	2 (3.6%)	2 (6.9%)	0 (0%)	0.385
Malignancy	4 (7.3%)	2 (6.9%)	2 (7.7%)	0.031

None of the above	8 (14.5%)	4 (13.8%)	4 (15.4%)	0.045
Outcomes				
Myocarditis	17 (30.9%)	11 (37.9%)	6 (23.1%)	0.327
Stroke	4 (7.3%)	1 (3.4%)	3 (11.5%)	0.311
Intubation	34 (61.8%)	21 (72.4%)	13 (50%)	0.473
STEMI	12 (21.8%)	7 (24.1%)	5 (19.2%)	0.119
New Heart Failure	55 (100%)	29 (100%)	26 (100%)	0
Cardiac Arrest	8 (14.5%)	8 (27.6%)	0 (0%)	0.873
Chest Compressions	11 (20%)	10 (34.5%)	1 (3.8%)	0.866
Pneumonia	14 (25.5%)	9 (31%)	5 (19.2%)	0.275
Torsades de Pointes / Sustained Ventricular Tachycardia	13 (23.6%)	10 (34.5%)	3 (11.5%)	0.567
Atrial Fibrillation / Atrial Flutter / Sustained Supraventricular Tachycardia	17 (30.9%)	8 (27.6%)	9 (34.6%)	0.152
Bradycardia requiring therapy	2 (3.6%)	1 (3.4%)	1 (3.8%)	0.021
VIS Max				
VIS > 0: Mean (SD)	261.3 (260.4)	323.5 (270.8)	173.6 (223.8)	0.619
VIS = 0	14 (25.5%)	5 (17.2%)	9 (34.6%)	0.404
SOFA Cardiovascular				
0	14 (25.5%)	4 (13.8%)	10 (38.5%)	0.571
1	0 (0%)	0 (0%)	0 (0%)	0
2	1 (1.8%)	0 (0%)	1 (3.8%)	0.283
3	12 (21.8%)	6 (20.7%)	6 (23.1%)	0.04
4	27 (49.1%)	18 (62.1%)	9 (34.6%)	0.621
Missing	1 (1.8%)	1 (3.4%)	0 (0%)	0.267
Troponin Max				
Normal	5 (9.1%)	1 (3.4%)	4 (15.4%)	0.527
High Risk	43 (78.2%)	27 (93.1%)	16 (61.5%)	0.527
Missing	7 (12.7%)	1 (3.4%)	6 (23.1%)	0.605
FiO2 Max				
Normal	10 (18.2%)	3 (10.3%)	7 (26.9%)	0.477
High Risk	39 (70.9%)	23 (79.3%)	16 (61.5%)	0.477
Missing	6 (10.9%)	3 (10.3%)	3 (11.5%)	0.038
PEEP Max (in Intubated or BiPAP patients)				
> 10	23 (41.8%)	15 (51.7%)	8 (30.8%)	0.211
≤10	11 (20%)	6 (20.7%)	5 (19.2%)	0.211

Table 2: Depicts risk of death associated with demographic and clinical variables for patients who experienced new onset heart failure.

Discussion

Our analysis of the CARDIO-COVID registry demonstrates that cardiovascular events are infrequent in severe COVID-19 disease and not significantly associated with mortality (**Central Figure**). By enriching our population for patients with lab evidence of myocardial injury and/or echocardiographic evidence of new myocardial dysfunction, we intended to select for patients most likely to be harboring a cardiovascular insult. Instead, the CARDIO-COVID cohort demonstrates that respiratory failure, cardiac arrest due to PEA, and septic shock are the primary causes of death.



Central Figure: Patients admitted to ICUs with severe COVID-19 and evidence of myocardial injury (top) most commonly die from sequelae of acute respiratory distress syndrome, i.e. respiratory failure, septic shock, and cardiac arrest mediated by prolonged hypoxemia. Despite every patient demonstrating evidence of myocardial injury in the setting of severe COVID-19, cardiovascular complications occur in ~15% of patients (mostly atrial fibrillation), and lead to patient death in 3% of cases (bottom left). Created with BioRender.com.

Consistent with prior cohorts, our population shows that elderly patients and those with risk factors for cardiovascular disease are at the highest risk for death. Troponin continues to demonstrate an association with poor outcome but not cardiovascular events. Instead, elevated troponin is associated with increased risk of severe lung injury, and degree of lung injury does not correlate with degree of troponin elevation. Similarly, high SOFA Cardiovascular and VIS scores carry an increased risk of death in both the general and heart failure cohorts, but the majority of these patients died from septic shock or hypoxemic respiratory failure. Rates of secondary bacterial pneumonia were significantly higher in patients with SOFA Cardiovascular scores >1 in both the general and heart failure cohorts suggesting sepsis as the predominant cause for hemodynamic compromise.

Cardiovascular complications of COVID-19 garnered significant attention throughout the pandemic. SARS-CoV2 virus enters cells via the angiotensin receptor, and early reports described troponin positivity being associated with poor outcomes suggesting that myocardial injury may be a source of pathogenesis. These reports were followed by studies from selected populations reporting increased risk of cardiovascular complications including heart failure, arrhythmia and cardiac arrest each being associated with increased risk of death. Studies from large, unselected populations failed to recapitulate the same risks of cardiovascular complications and, conversely, demonstrate a low incidence (< 1%) of death attributable to cardiovascular causes [16-19]. Results from CARDIO-COVID, despite being a population of patients thought to be enriched for cardiovascular complications, reflect similarly low individual rates of cardiovascular complications, low incidence of cardiovascular

death, high incidence of non-cardiogenic shock, and high incidence of all-cause mortality. Unique to this study, cause of death data was adjudicated by site investigators directly involved in patient care during the pandemic, and their observations corroborated our LightGBM model demonstrating that the overwhelming causes of death were respiratory failure and septic shock.

Given the low event rate, a LightGBM model is particularly well suited to analyze the impact of cardiovascular events [20]. LightGBM decision trees efficiently identify high magnitude but low frequency events, distinct high-risk subgroups, and non-linear risk relationships [21]. We show that cardiovascular events are not only infrequent but do not carry outsized risk of death. Our model demonstrated high accuracy, sensitivity, and specificity when using age, intubation, SOFA Cardiovascular score, and troponin to predict ICU mortality. Our model identified PEA as a rare but high-risk event then appropriately weighted PEA lower given the absence of PEA was not protective for survival. We did not see a similar effect for any cardiovascular complications.

While our findings describe low risks of cardiovascular complications of COVID-19, rare cases of acute, fulminant heart failure due to myocarditis have been described [11]. Though myocarditis can be catastrophic, incidence of myocarditis in COVID-19 is < 0.15% in hospitalized patients [22] and the majority of these patients do not experience hemodynamic insults. It is also important to note that degree of troponin and natriuretic peptide elevation are not dissimilar between severe myocarditis associated with heart failure and patients with severe lung COVID-19 lung disease.

Cardiac biomarkers have been recognized as valuable indicators of critical illness. Severe systemic inflammation from sepsis and exacerbations of chronic lung disease have been shown to be associated with significant elevations in troponin and natriuretic peptide when cardiac function and filling pressures are normal [23, 24]. Inflammatory cytokines and proteins have been used to phenotype Acute-Respiratory-Distress Syndrome (ARDS), both offering insights into disease mortality and novel treatment opportunities [25]. In severe COVID-19 troponin has more recently been recognized as an indicator of hyperinflammatory ARDS, a disease process that that responds more favorably to corticosteroids than hypo inflammatory ARDS phenotypes [26]. Recognizing elevated cardiac biomarkers may indicate hyperinflammatory lung injury could both expedite appropriate treatment of ARDS and avoid unnecessary cardiac diagnostics.

The primary limitations of the CARDIO-COVID registry are the retrospective nature of the data collection as well as the high degree of missingness. While retrospective data carries opportunities for unrecognized bias, the infrequent nature of cardiovascular events in COVID makes prospective data collection challenging. We selected for patients at greatest risk for cardiac complications to minimize the chance that cardiovascular complications are underrepresented.

The high degree of missingness is explained by the most affected variables coming from the serial vital sign's sheets, which were not required entries. Furthermore, handling of patients with missing variables as an independent group did not affect relationships between demographics, comorbidities, or use of ICU therapies and mortality or mode of death.

Given the investigator-initiated nature of the study and stressed working conditions of the pandemic, missing data is a common challenge. By analyzing missingness as an independent variable we showed that within this dataset missingness does not appear to bias associations. Missingness was most common in the daily ICU flow sheet data form, which was an optional data field for investigators. Outcomes and cause of death data had a high rate of completeness rendering the low cardiovascular event rates and associations likely valid. These findings are similar to studies using from inpatient datasets not enriched for cardiovascular involvement [19].

Conclusion

The primary strengths of the registry are the multinational structure, enriched patient population, duration of the study, and investigator driven data entry. The multinational structure and duration of the study allow for the associations to describe outcomes for multiple SARS CoV-2

variants. Data entry was performed by investigators with direct knowledge of patient care and outcomes. This allowed for a high degree of data fidelity and collection of cause of death.

Clinical Perspective

Cardiovascular events are less significant drivers of mortality in severe COVID-19 than previously described. In a population thought to be at high risk for cardiovascular death based on early data published in the COVID-19 Pandemic, the overwhelming causes of mortality were hypoxemic respiratory failure and septic shock [27, 28]. Biomarkers of cardiac injury may represent a hyperinflammatory ARDS phenotype rather than significant myocardial injury in the majority of cases [29].

Acknowledgement

Much of this work was completed during the COVID-19 pandemic with minimal funding and institutional support. The authors would like to recognize Marina Mekhaeil (St. Michael's Hospital), Federico Baldass (St. Michael's Hospital).

References

- 1) Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020, 46:846-848.
- 2) Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. *N Engl J Med.* 2020,1:1-8.
- 3) Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, et al. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. *JACC Basic to Transl Sci.* 2020, 5:518-536.
- 4) Basso C, Leone O, Rizzo S, De Gaspari M, Van Der Wal AC. Pathological features of COVID-19-associated myocardial injury: A multicentre cardiovascular pathology study. *Eur Heart J.* 2020, 41:3827-3835.
- 5) O'donnell C, Ashland MD, Vasti EC, Ying Lu, Andrew YC, et al. N-terminal pro-b-type natriuretic peptide as a biomarker for the severity and outcomes with covid-19 in a nationwide hospitalized cohort. *J Am Heart Assoc.* 2021, 21;10:e022913.
- 6) Szekely Y, Lichter Y, Taieb P, Banai A, Merdler I, et al. The spectrum of cardiac manifestations in coronavirus disease 2019 (covid-19)- a systematic echocardiographic study. *Circ.* 2020, 29:342-353.
- 7) Coromilas EJ, Kochav S, Goldenthal I, Biviano A, Garan H, et al. Worldwide survey of covid-19 associated arrhythmias. *Circ Arrhythmia Electrophysiol.* 2021, 14:e009458.
- 8) Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (covid-19). *JAMA Cardiol.* 2020, 5:1265-1273.
- 9) Varshney AS, Omar WA, Goodrich EL, Bhatt AS, Wolley AE, et al. Epidemiology of cardiogenic shock in hospitalized adults with covid-19: a report from the american heart association covid-19 cardiovascular disease registry. *Circ Heart Fail.* 2021, 14:e008477.
- 10) Fairweather DL, Beetler DJ, Di Florio DN, Musick N, Heidecker B, et al. COVID-19, myocarditis and pericarditis. *Circ Res.* 2023, 132:1302-1319.
- 11) Barhoum P, Chambrun MP De, Dorgham K, Mathieu K, Sonia B, et al. Phenotypic heterogeneity of fulminant covid-19-related myocarditis in adults. *J Am Coll Cardiol.* 2022,80:299-312.
- 12) Halushka MK, Vander RS. Myocarditis is rare in COVID-19 autopsies : cardiovascular findings across 277 postmortem examinations. *Cardiovasc Pathol.* 2021, 50:107300.
- 13) Li Y, Fang L, Zhu S, Xie Y, Wang B, et al. Echocardiographic characteristics and outcome in patients with covid-19 infection and underlying cardiovascular disease. *Front Cardiovasc Med.* 2021, 8:1-12.
- 14) Pournazari P, Spangler AL, Ameer F, Hagan KK, Tano ME, et al. Cardiac involvement in hospitalized patients with COVID-19 and its incremental value in outcomes prediction. *Sci Rep.* 2021, 11:1-8.
- 15) Guan W-J, Ni Z-Y, Hu Y, Liang WH, Quan Ou C, et al. Clinical characteristics of coronavirus disease 2019 in china. *N Engl J Med.* 2020, 1:1-13.
- 16) Sokolski M, Trenson S, Sokolska JM. Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. *ESC Hear Fail.* 2021, 8:4955-4967.
- 17) Fumagalli S, Trevisan C, Del Signore S, Pelagalli G, Fumagalli C, et al. Atrial fibrillation and COVID-19 in older patients: how disability contributes to shape the risk profile. An analysis of the gerocovid registry. *Aging Clin Exp Res.* 2022, 34:249-256.

- 18) Marijon E, Karam N, Jouven X. Cardiac arrest occurrence during successive waves of the COVID-19 pandemic: direct and indirect consequences. *Eur Heart J*. 2021, 42:1107-1109.
- 19) Hall EJ, Ayers CR, Kolkailah AA, Rutan C, Walchok J, et al. Longitudinal trends in cardiovascular risk factor profiles and complications among patients hospitalized for covid-19 infection: results from the american heart association covid-19 cardiovascular disease registry. *Circ Cardiovasc Qual Outcomes*. 2023, 16:E009652.
- 20) Ke G, Meng Q, Finley T, Wang T, Chen W, et al. LightGBM: A highly efficient gradient boosting decision tree. *Adv. Neural Inf. Process. Syst*. 2017.
- 21) Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, et al. From local explanations to global understanding with explainable ai for trees. *Nat Mach Intell*. 2020, 2:56-67.
- 22) Boehmer T, Kompaniyets L, Lavery A, Hsu J, Yusuf H, et al. Association between covid-19 and myocarditis using hospital-based administrative data-united states. *MMWR Morb Mortal Wkly Rep*. 2021, 70:1228-1232.
- 23) Rudiger A, Gasser S, Fischler M, Hornemann T, Von Eckardstein A, et al. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. *Crit Care Med*. 2006, 34:2140-2144.
- 24) Adrish M, Nannaka VB, Cano EJ, Bajantri B, Diaz-Fuentes G. Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction. *Int J COPD*. 2017, 12:1183-1189.
- 25) Maddali M V., Churpek M, Pham T, Rezoagli E, Zhuo H, et Al. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. *Lancet Respir Med*. 2022, 10:367-377.
- 26) Sinha P, Furfaro D, Cummings MJ, Abrams D, Delucchi K, et al. Latent class analysis reveals covid-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids. *Am J Respir Crit Care Med*. 2021, 204:1274-1285.
- 27) Kole C, Stefanou E, Karvelas N, Schizas D, Toutouzas KP. Acute and post-acute covid-19 cardiovascular complications: a comprehensive review. *Cardiovasc Drugs Ther*. 2024, 38:1017-1032.
- 28) Guo T, Fan Y, Chen M, Wu X, Zhang L, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (covid-19). *JAMA Cardiol*. 2020, 5:811-818.
- 29) Efros O, Soffer S, Leibowitz A, Fardman A, Klempfner R, et al. Risk factors and mortality in patients with pneumonia and elevated troponin levels. *Sci Rep*. 2020, 10:1-7.